Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Biogen Poaches Merck Exec to Lead New Marketing Team November 2, 2017 Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks October 10, 2017 <b>Spruce Biosciences</b> Provides Corporate Update On Series A Venture Financing, Leadership Team And Lead Clinical Program October 11, 2017
<b>Spruce Biosciences</b> Provides Corporate Update On Series A Venture Financing, Leadership Team And Lead Clinical Program October 11, 2017
